/Tpl2
−/− mice exhibit a fivefold increase in the number of intestinal adenomas. Bone marrow transplantation experiments revealed that the enhancement of polyposis was partially hematopoietic cell-driven. Consistent with this observation, Tpl2 ablation promoted intestinal inflammation. IL-10 levels and regulatory T-cell numbers were lower in the intestines of Tpl2
mice, independent of Apc and polyp status, suggesting that they were responsible for the initiation of the enhancement of tumorigenesis caused by the ablation of Tpl2. The low IL-10 levels correlated with defects in mTOR activation and Stat3 phosphorylation in Toll-like receptor-stimulated macrophages and with a defect in inducible regulatory T-cell generation and function. Both polyp numbers and inflammation increased progressively with time. The rate of increase of both, however, was more rapid in Apc min/+ /Tpl2
−/− mice, suggesting that the positive feedback initiated by inflammatory signals originating in developing polyps is more robust in these mice. This may be because these mice have a higher intestinal polyp burden as a result of the enhancement of tumor initiation.
inflammatory bowel disease | TNF-α | IL-6 | Tr1 cells | Th17 cells G enetic susceptibility to colorectal carcinogenesis has been linked to a host of germ-line mutations that give rise either to familial adenomatous polyposis (FAP) or to hereditary nonpolyposis colorectal cancer. FAP is caused by germ-line mutations of the APC gene and is characterized by the development of large numbers of intestinal polyps early in life. Some of these polyps ultimately progress to give rise to malignant colorectal tumors. APC (adenomatous polyposis coli) gene mutations are detected in at least 95% of human malignant colorectal tumors, including tumors arising in individuals who do not carry germ-line APC mutations, suggesting that it plays a critical role in both familial and sporadic intestinal tumorigenesis. Germ-line mutations of the APC gene in mice give rise to a syndrome that is similar to the FAP syndrome in humans. Mice carrying the Apc min mutation have been used extensively as an animal model to study intestinal polyposis and cancer (1) .
APC mutations promote intestinal tumorigenesis by cell-autonomous as well as stroma-dependent processes. Earlier studies had shown that inflammatory infiltrates consisting of F4/80/ CD11b double-positive macrophages, Gr1/CD11b double-positive myeloid-derived suppressor cells, and other types of inflammatory cells (e.g., mast cells) accumulate in the intestinal mucosa of APC mutant mice and contribute to oncogenesis (2) (3) (4) (5) . Moreover, intestinal inflammation promotes oncogenesis in humans and animals even in the absence of germ-line mutations in the APC locus. Thus, inflammatory bowel disease has been linked to an increased incidence of cancer (6) . In addition, high levels of nitric oxide, as well as overexpression of the proinflammatory cytokines TNF-α and IL-6, promote intestinal oncogenesis (7, 8) , whereas antiinflammatory agents, such as neutralizing TNF-α antibodies (5), inhibit it. Similarly, inhibitors of the proinflammatory mediators COX-2 and prostaglandins decrease intestinal inflammation and the incidence of colon adenocarcinomas in humans and genetically susceptible mice (9) , whereas intestinal bacterial infections, which increase the expression of COX-2, promote both (10) . In agreement with these findings, the number of intestinal polyps in Apc 
/EP2
−/− double-mutant mice was lower than in Apc Δ716/+ single mutants (11) . A stroma-derived inhibitor of inflammation and oncogenesis is IL-10, an antiinflammatory cytokine produced by macrophages, dendritic cells, and T cells, including Foxp3
+ and Foxp3 − regulatory T cells (Tregs). The importance of IL-10 in intestinal homeostasis was confirmed by the finding that Il10 KO mice develop intestinal inflammation (12, 13) and are more susceptible to colonic carcinogenesis induced by APC mutations than WT mice (12) . Intestinal IL-10 is produced primarily by macrophages and is essential for the control of inflammation in the colon. One of the functions of macrophage IL-10 is the maintenance of Foxp3 expression in Tregs, which become functionally defective in its absence (14) . IL-10 regulation in macrophages and dendritic cells is under the control of Stat3 (15) , which is activated by Toll-like receptor (TLR) and cytokine signals (15, 16) . Experiments based on either genetic or pharmacological inhibition have shown that Stat3 phosphorylation and IL-10 induction by TLR signals depend on mTOR activation (15) . KO of Stat3 in myeloid cells exhibits a similar phenotype to the KO of Il10 (17), underscoring the importance of Stat3 activation in myeloid cells for the induction of IL-10.
Tregs also suppress intestinal inflammation and tumorigenesis in Apc min/+ mice (3, 18) , and they are protective in a variety of human tumors, including sporadic colon cancer (19) , colon cancer associated with defects in mismatch repair (20) , gastric cancer (21) , and head and neck cancer (22) . Moreover, WT but not IL-10-deficient Tregs adoptively transferred in Apc min/+ mice inhibit both intestinal inflammation and tumorigenesis (3, 18, 23) . Finally, in the course of progressive polyposis in mice and humans, Tregs tend to lose expression of IL-10, reversing their function from antiinflammatory to proinflammatory (2, 3).
The latter two observations are consistent with the finding that Treg-specific ablation of Il10 results in bacteria-dependent inflammatory bowel disease (IBD) in aging mice (24) .
The Tpl2 protooncogene encodes a serine-threonine protein kinase that is activated by provirus integration in Moloney MuLV-induced T-cell lymphomas and mouse mammary tumor virus (MMTV)-induced mammary adenocarcinomas in mice (25, 26) . When overexpressed in a variety of cell types, Tpl2 activates ERK, JNK, p38MAPK, and the transcription factors NFAT (nuclear factor of activated T cells) and NF-κB (27, 28) . Moreover, transgenic mice expressing a constitutively active form of Tpl2 under the control of a T cell-specific promoter develop thymic lymphomas with a mean latency of 3 mo (29) . Despite these profound effects of Tpl2 overexpression, Tpl2 KO mice generated to study the physiological role of Tpl2 in intact animals appear normal (30) . Studies using these mice revealed that Tpl2 is required for the transduction of signals induced by TLR ligands, IL-1β, TNF-α, CD40L, TCR, and G protein-coupled receptor (GPCR) ligands (30) (31) (32) (33) (34) . One pathway that is reproducibly impaired by the ablation of Tpl2 in different types of cells following exposure to a variety of stimuli is the ERK pathway. Recent studies have shown that Tpl2 ablation impairs the induction of IL-10 by LPS (TLR4)-and CpG (TLR9)-induced ERK activation signals in both macrophages and dendritic cells (35) .
TLR signaling has a critical role in spontaneous tumor development in APC-defective mice. Apc min/+ mice defective for the myeloid differentiation response gene 88 (MyD88), an obligatory downstream target of TLR4 and TLR2, are protected from polyposis (36 
/Tpl2
−/− mice to intestinal tumorigenesis is partially driven by hematopoietic cells. Consistent with this observation, the ablation of Tpl2 in Apc min/+ mice was shown to promote the establishment of a proinflammatory environment that stimulates oncogenesis in the intestinal mucosa. The earliest events in the sequence that leads to inflammation and tumorigenesis appeared to be the secretion of IL-10 and the generation of inducible Tregs (iTregs), both of which were impaired in Tpl2 −/− mice. The low levels of IL-10 and the low number and functional impairment of Tregs promote inflammation and tumorigenesis in the context of the Apc min mutation. Polyp numbers and inflammation increased progressively with time in both Apc min/+ /Tpl2 +/+ and Apc min/+ /Tpl2 −/− mice, but the rate of increase in both was higher in the Apc min/+
−/− mice. The latter observation suggested that Tpl2 ablation may stimulate positive feedback mechanisms that promote the acceleration of polyposis. Given that polyps give rise to proinflammatory and prooncogenic signals, this may be attributable to the enhancement of tumor initiation, which increases the tumor burden and gives rise to a more robust proinflammatory environment in these mice throughout life. Collectively, these observations provide evidence that Tpl2 has a critical role in the regulation of systemic inflammation and in the susceptibility to intestinal tumorigenesis. +/+ mice were monitored over a period of up to 150 d for tumor induction. Mice exhibiting signs of systemic illness were killed and autopsied. The survival curves of the two experimental groups are shown in Fig. 1B , which combines survival data of both male and female mice. Plotting the data separately for male and female mice revealed no differences between the sexes.
Results

Tpl2
Evaluation of the number of polyps formed in Apc 
/Tpl2
−/− mice ( Fig. 1C and Fig. S1A ). Plotting the distribution of polyps along the small intestine (proximal, middle, and distal sections) and the colon revealed that Tpl2 ablation significantly increases the number of polyps in all parts of the intestine but that it does not alter the polyp distribution ( −/− mice carrying the Apc min mutation could be the result of a cell-autonomous defect in the intestinal epithelia. Alternatively, it may be attributable to tumor-promoting changes in the intestinal stroma. The latter is supported by the results of earlier studies suggesting that the main function of Tpl2 is the regulation of innate and adaptive immunity (30, 33, 35, 37, 38 (Fig. S2) . The results showed that if Tpl2 is disrupted only in hematopoietic cells, its ablation is not sufficient to induce the tumor enhancement phenotype (Fig. 1D, Right) . Therefore, the ablation of Tpl2 in hematopoietic cells is necessary but not sufficient to elicit the Tpl2 −/− intestinal phenotype in Apc min/+ mice. Earlier studies had shown that inhibition of TLR signal-induced ERK activation in epithelial cells protects from Apc mininduced intestinal tumorigenesis (39, 40) . Given that Tpl2 is required for ERK activation by TLR signals in different cell types (30, 41) , one would expect that Tpl2 ablation would inhibit polyposis. However, Tpl2 ablation had the opposite effect, making the possibility that enhancement of intestinal tumorigenesis depends on the inhibition of TLR signaling in the intestinal epithelia unlikely.
Tpl2 Ablation Promotes the Establishment of a Proinflammatory
Environment in the Intestinal Mucosa. Inflammation plays a critical role in intestinal tumorigenesis (6, 42) . This fact, combined with the results of the bone marrow transplantation experiments described above, raised the possibility that Tpl2 ablation may promote Apc (Fig. 2F ). In the absence of the Apc min mutation, the ablation of Tpl2 failed to alter the composition of the intestinal inflammatory infiltrates (Fig. S4) and to enhance the levels of TNF-α and IL-6 in the intestinal mucosa ( 
/Tpl2
−/− mice were treated with an antibiotic regimen that inhibits intestinal tumorigenesis in Nod1-deficient mice (44) . Pregnant mothers in the last trimester of pregnancy were treated with streptomycin, gentamicin, ciprofloxacin, and bacitracin, as described in SI Materials and Methods. The results showed that the severity of polyposis in the small intestines was not affected by the antibiotics ( 
−/− mice precede or follow the differences in intestinal inflammation between the two strains. We therefore embarked on intestinal cytokine measurements at different time points, aiming to identify differences between these 
−/− mice showed that the levels of intestinal IL-10 were lower in Tpl2 −/− mice than in Tpl2 +/+ mice, both in the WT and Apc min/+ backgrounds (Fig. 3A) . The difference in IL-10 expression in the intestines of Tpl2 +/+ and Tpl2 −/− mice was observed in both young and older mice. The observation that Tpl2 ablation is associated with low levels of intestinal IL-10 before the detection of inflammation and polyp formation suggests that the reduced IL-10 expression in these mice may be one of the initiating factors for inflammation and tumorigenesis, even though it may not be sufficient to induce these processes by itself.
IL-10 is produced by a variety of cell types, including macrophages, dendritic cells, and T cells. It has been proposed that F4/ 80 + /CD11b
+ macrophages are mostly responsible for IL-10 production in the intestines (14, 46) . Previous studies had shown that Tpl2 ablation gives rise to a macrophage and dendritic cell defect in the induction of IL-10 by TLR signals (35) . Following confirmation of this finding (Fig. S6) , we embarked on studies to determine the mechanism by which Tpl2 regulates IL-10 expression in macrophages in response to TLR signals. IL-10 induction by TLR signals is blocked by mTOR inhibitors, such as rapamycin. The latter inhibits IL-10 induction by inhibiting the phosphorylation of Stat3, an upstream regulator of IL-10 (15). To examine whether Tpl2 ablation inhibits the induction of IL-10 by TLR signals, also by inhibiting mTOR activation and Stat3 phosphorylation, lysates of Tpl2 +/+ and Tpl2
bone marrow-derived macrophages (BMDMs) harvested before and after stimulation with LPS were probed with phosphoantibodies specific for mTOR, p70S6K, Stat3, and ERK (control). The results show that, similar to mTOR inhibition, Tpl2 ablation in macrophages inhibits mTOR, p70S6K, and Stat3 phosphorylation by TLR signals (Fig. 3B ). These findings suggest that −/− mice, mononuclear cells prepared from collagenase-digested gut tissue were stained with antibodies that recognize T-cell surface markers and intracellular Foxp3, and they were analyzed by flow cytometry. The results (Fig. 4 A-C) revealed that the intestines of Tpl2 −/− mice contain lower numbers of Foxp3 + Tregs than the intestines of Tpl2 +/+ mice and that the difference is independent of polyposis. Moreover, the correlation between Tpl2 ablation and the reduction in the number of intestinal Tregs was observed in both young (5-and 7-wk-old) Apc min/+ mice, which carry only a small number of micropolyps, and older (3-mo-old) polyp-bearing Apc min/+ mice. The Treg defect extended also in the spleen and the lymph nodes of Tpl2 −/− mice (Fig. 4D) . We conclude that the ablation of Tpl2 in both the Apc +/+ and Apc min/+ genetic backgrounds gives rise to a generalized regulatory T-cell defect that is not limited to the intestines.
Foxp3
+ Tregs are generated in the thymus [natural Tregs (nTregs)], and they are dispersed in the periphery. Alternatively, they are induced extrathymically in the course of the T-cell response to external signals (iTregs) (47 −/− mice with a Foxp3 antibody revealed no Tpl2-dependent differences in the number of thymic nTregs (Fig. 4E) . Therefore, Tpl2 ablation gave rise to a Treg defect that was limited to extrathymic tissues. We conclude that the ablation of Tpl2 does not affect the generation of nTregs in the thymus. (Fig. S7) showed that in the younger age group, the numbers of CD4 /Tpl2 +/+ mice, but the differences were not statistically significant (Fig. 6A) . In the older age group however, the differences were significant (Fig. 6B) . −/− mice in both age groups. However, the difference was statistically significant only in the older age group (Fig. 6D) , suggesting that the accumulation of the proinflammatory Th17 cells increases with age but that the increase is disproportionately more pronounced in Apc 
/Tpl2
−/− mice may produce a more robust proinflammatory environment than polyps developing in Apc min/+ /Tpl2 +/+ mice. Given the importance of inflammation in intestinal tumorigenesis, the preceding data prompted us to examine the rates by which the numbers of polyps increase with time in Apc min/+ / Tpl2 −/− and Apc min/+ /Tpl2 +/+ mice. We predicted that if the number of polyps correlated positively with the percentage of Th17 cells and negatively with the percentage of Tregs, the polyp number would increase more rapidly in Apc min/+ /Tpl2 −/− mice. Initial support of the aforementioned prediction was provided from measurements of the size of the polyps. These measurements revealed small (<2 mm), medium (2-3 mm), and large (3-4 mm) polyps. Very large polyps (>4 mm) were few in number, they were only detected in the colon, and they were not included in this analysis. The number of polyps was higher in Apc min/+ / Tpl2 −/− mice than in Apc min/+ /Tpl2 +/+ mice across all size categories. However, the difference was more pronounced in the small size category rather than in the large size category (Fig.  6E) . We reasoned that if the large polyps were the earliest to develop and the small polyps were the latest, the rate of development of new polyps should increase with time and the increase should be more rapid in the Apc min/+ /Tpl2 −/− mice than in the Apc min/+ /Tpl2 +/+ mice. To address this hypothesis, we measured the number of polyps in the two mouse groups at different time points. Plotting the change in polyp number over time confirmed the prediction (Fig. 6F) .
The correlation between the rates by which the numbers of 
−/− mice were attributable to the higher number of polyps in these mice. If this was the case, the enhanced inflammatory environment associated with the higher number of polyps in Apc min/+ /Tpl2 −/− mice would perhaps promote the development of additional polyps. However, it would not explain how the interdependent processes of inflammation and tumorigenesis were initiated in the first place. Given the known role of Tpl2 in the regulation of innate immunity and the results of the bone marrow transplantation experiment, we hypothesized that Tpl2 ablation induced inflammation and that the enhanced tumorigenesis observed in the Apc min/+ /Tpl2 −/− mice was secondary to the more severe intestinal inflammation in these mice. To address this hypothesis, we embarked on studies aiming to determine whether intestinal inflammation can be detected in the intestinal mucosa of Apc +/+ /Tpl2 −/− mice that do not develop polyps, and whether it precedes polyp formation in IL-10 is produced by a variety of cell types, including macrophages and dendritic cells. More importantly, IL-10 induction by TLR signals in these cells depends on Tpl2 (35) . Experiments reported here confirmed these data. In addition, they showed that LPS-stimulated Tpl2 −/− macrophages express higher levels of IL-12p40 and IFN-β than LPS-stimulated Tpl2 +/+ macrophages. Combined, these data indicate that Tpl2 ablation in macrophages gives rise to an LPS stimulation phenotype that is similar to the phenotype of LPS-stimulated and TORC1-inhibited WT macrophages (15, 16) . Based on these considerations, we examined whether Tpl2 ablation in macrophages interferes with the activation of mTOR and the phosphorylation of the Stat3 in LPS-stimulated macrophages. The results confirmed that Tpl2 is required for both mTOR activation and Stat3 phosphorylation. (Fig. 7) .
In summary, the data in this report provide a previously undescribed genetic link between inflammation and cancer. Moreover, the Tpl2 ablation model provides a valuable tool to address the pathophysiology of IBD and colorectal cancer mechanistically in animals and humans.
Materials and Methods
Mice. Tpl2 KO mice were described previously (30) . Apc min/+ mice were purchased from The Jackson Laboratory. Both strains of mice were in the C57BL/6 background.
Polyp Counting and Histopathological Analysis. Intestines were removed, washed with PBS, and cut into four pieces (proximal, middle, and distal small intestine and colon). The number and size of the macroscopic polyps were measured in longitudinally opened intestines under a dissecting microscope. For the Swiss roll preparations, intestines were removed, flushed with PBS, opened longitudinally, rolled, and fixed in 10% (vol/vol) buffered formalin. Paraffin sections were stained with H&E and examined microscopically.
Mononuclear Cell Isolation and FACS Analysis. Isolation of mononuclear cells from the intestines and antibody staining were carried out using standard procedures (3). Staining was monitored by flow cytometry. (Details are provided in SI Materials and Methods.) Splenocytes, lymph node cells, and thymocytes were isolated as previously described (30) , and they were stained with the antibodies also used to stain the mononuclear cells isolated from the intestinal mucosa. (Details are provided in SI Materials and Methods.)
Western Blotting. BMDMs were prepared as described previously (30) . Serumstarved BMDMs were stimulated with 1 μg/mL LPS (Escherichia coli 0:111; Sigma), and they were harvested at the indicated time points. Western blots of the BMDM lysates and lysates of adenomas removed from the mouse small intestines were probed with the indicated antibodies. mice and Tpl2 −/− bone marrow transplanted into Tpl2 +/+ mice) (Fig. S2) . Measurement of Cytokine Levels. BMDMs were stimulated with LPS (1 μg/mL) for 3-12 h. Selected cytokines were measured in the culture media by ELISA, using kits from BD Biosciences (IL-10), R&D Systems (IL-12p70), and the PBL (Pestka Biomedical Laboratories) interferon source (IFN-β). mRNA levels of IL-10, IL-12p35, IL-12p40, and IFN-β were measured in the same cells by realtime RT-PCR with GAPDH as the internal control (the primers are shown in Table S1 ). Measurement of Cytokine Levels. Cytokine levels in LPS-stimulated BMDMs were measured by real-time RT-PCR. The primers are shown in Table S1 . Total RNA for this experiment was isolated using TRIzol (Invitrogen). cDNA was generated using Retroscript (Ambion).
To measure the level of cytokines in the intestines, 1-to 2-cm pieces of the small intestine were homogenized in cold 50 mM Tris·HCl (pH7.5) containing PMSF and protease inhibitors (Sigma). Samples were cleared by centrifugation, and the supernatants were stored at −80°C. Cytokine levels were measured by ELISA kits for IL-10, TNF-α, and IL-6 (all from BD Biosciences). ), single-cell suspensions of mouse splenocytes were stained with anti-CD4-PE-Cy7 (GK1.5; eBioscience), anti-CD62L-FITC (MEL-14; PharMingen), anti-CD8-PE (53-6.7; eBioscience), and anti-CD25-APC (PC61.5; eBioscience) antibodies, and they were FACS-sorted using a MoFlow sorter (DakoCytomation).
Naive CD4 + T cells (2 × 10 5 ) and irradiated antigen-presenting cells (8 × 10 5 ) were cocultured in RPMI medium 1640 supplemented with 10% (vol/vol) FBS, antibiotics, nonessential amino acids, and L-glutamine. Cells were stimulated with soluble anti-CD3 (1 μg/mL, clone 145-2C11; eBioscience), anti-CD28 (2 μg/mL, clone 37.51; eBioscience), and recombinant TGF-β1 (4 ng/mL; R&D Systems) for 5 d. To block cytokine secretion, we added GolgiStop in some of the cultures 3 h before harvesting.
For intracellular staining, cells were fixed with 0.5% PFA, permeabilized with 0.5% saponin, and stained with antiFoxp3-Alexa Fluor 647 (FJK-16s; eBioscience) and anti-IL-10-PE (JES5-16E3; eBioscience) antibodies. Cell staining was monitored using a CyAn flow cytometer (DakoCytomation), and the results were analyzed using Summit v4.3 software (DakoCytomation). mice is generally larger than the size of the spleen of 3-mo-old Apc min/+ /Tpl2 +/+ mice. *P < 0.05; **P < 0.01. −/− mice and 9 Apc min/+ /Tpl2 +/+ mice were treated with the indicated antibiotic regimen, and they were euthanized at the age of 6.5 or 10 wk. n.s., not significant. Legend continued on following page mice (B) (5 per genotype) were stained with anti-CD4, anti-CD25, and anti-Foxp3 antibodies, and they were analyzed by flow cytometry. Cells were gated for CD25 + , and they were analyzed for the expression of CD4 and Foxp3. 
